• Have the ability to sign the written informed consent;

• Ductal adenocarcinoma of the pancreas confirmed by histopathology or cytopathology;

• Distant metastasis was excluded by imaging assessment (PET-CT, cranial MRI), and was defined as locally advanced unresectable according to NCCN Guidelines Version 2022.1, that is, T4N0-2M0, Stage III (AJCC/UICC Version 8);

• The maximum diameter of pancreatic primary lesion and positive lymph node ≤7cm;

• Pancreas primary lesion or positive lymph node did not invade digestive tract (stomach, duodenum and small intestine);

• Eastern Cooperative Oncology Group (ECOG) performance score 0-1;

• Adequate bone marrow function (neutrophil count ≥1.5×109/L, platelet count ≥100×109/L, hemoglobin ≥10.0g/dL);

• Adequate liver function (total bilirubin \<1.5 times the upper limit of normal value, aminotransferase \<2.5 times the upper limit of normal value);

• Adequate renal function (serum creatinine \<2mg/dL, or creatinine clearance \>50mL/min).